Multinational pharmaceutical companies remain confident in the Chinese market and are determined to deepen their development

【Pharmaceutical Network Industry News】The Chinese market has always been an important market
in the global strategy of multinational pharmaceutical companies.
Statistics show that in 2021, China's pharmaceutical industry achieved revenue of 3,370.
75 billion yuan, a new growth
rate in the past five years.
In the five years from 2016 to 2021, China has launched a total of 280 new drugs, of which multinational pharmaceutical companies contributed more than
half.
Recently, RDPAC revealed that internal research shows that more than 90% of multinational pharmaceutical companies said that the strategic importance of the Chinese market in their global world will remain stable
in the next 3 to 5 years.
It can be seen that multinational pharmaceutical companies still have confidence in the Chinese market and are determined
to deepen their development.
At the CIIE held on November 5, multinational giants such as Johnson & Johnson, Pfizer, Roche Pharmaceutical, AbbVie, Novartis, Merck, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, AstraZeneca, Takeda Pharmaceutical, Eli Lilly, Bayer, Gilead, Amgen and other multinational giants gathered together, including Pfizer, Novartis, Roche, Johnson & Johnson and other companies have launched their first new products, showing optimism about
the growth potential of China's pharmaceutical market and the development opportunities of innovative drugs 。 For example, AbbVie brought the company's first upcoming solid tumor product, Teliso-V, a first-of-its-kind antibody conjugate under development that received breakthrough therapy designation from the U.
S.
FDA earlier this year for the treatment
of non-small cell lung cancer.
According to media materials, Merck launched the world's first authorized anti-new coronavirus oral drug at the Expo, which has been approved or authorized for emergency use in more than 40 countries or regions around the world
.
In September this year, Merck granted Sinopharm the distribution right and exclusive import right of the drug in China, and held another cooperation signing ceremony
for the drug on November 7.
Pfizer showcased more than 20 innovative products, covering five major fields
: oncology, vaccines, anti-infection, inflammation and immunity, and rare diseases.
These include the first CGRP receptor antagonist with a rapidly dissolving oral disintegration tablet form, remegipam, which is currently the first oral CGRP receptor antagonist
approved for the treatment and prevention of migraine.
In addition, many multinational pharmaceutical companies hope to find more opportunities in the Chinese market, including exploring innovative research and development, win-win cooperation, digital intelligence, etc.
, and the news of the "marriage" related to this Expo continues to come
。 For example, Johnson & Johnson announced at the meeting that it "joined hands" with Hangzhou Duoxi Biologics to jointly develop new ADC drugs; 10 pharmaceutical and diagnostic companies, including AstraZeneca, Daiichi Sankyo, Hutchison Pharmaceutical, Roche Diagnostics and Ader Biologics, announced the establishment of the MET HER2 Precision Diagnosis Alliance; Sanofi announced that it will announce another cooperation with JD Health, expanding the existing cooperation from the field of chronic diseases to the field of atopic dermatitis (AD), and meeting the more diversified health needs
of atopic dermatitis patients in the digital era by creating the first one-stop AD online full-course management platform.
It is reported that in order to better serve Chinese patients, a large number of multinational pharmaceutical companies have set up factories and built R&D centers
in Chinese mainland.
According to the data, by June 2020, multinational pharmaceutical companies have set up 47 factories and 25 R&D centers in Chinese mainland, with an annual R&D investment of more than 12 billion yuan and more than 130,000 employees in Chinese mainland
.
Among them, Sanofi has 4 R&D centers, Novartis has 3, Bayer, Pfizer, Xi'an Janssen has 2.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.